Alumis Inc.
ALMS
Peringkat dalam Saham
#10084
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.61
Kapitalisasi Pasar
$854.92M
Perubahan (1 hari)
4.18%
Perubahan (1 tahun)
190.97%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Riwayat pemecahan saham untuk Alumis Inc. (ALMS)
Saham Alumis Inc. (simbol: ALMS) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham ALMS yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham ALMS.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham ALMS yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham ALMS.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
